Apple Fitness Plus Targets GLP-1 Users With New Weight-Loss Partnership
FuturHealth offers personalized weight loss guidance and medications with the help of licensed dietitians and doctors. These include GLP-1 agonists such as semaglutide -- better known as Ozempic. It's partnered with Valisure, a tech company that provides independent quality assurance, to guarantee it's following safe and high-quality standards for weight loss medications. The company says most members see the greatest success when combining exercise, high-quality weight loss medications and a healthy diet.
According to a report from FAIR Health, between 2019 and 2024, the percentage of adult patients prescribed a GLP-1 drug went up from 0.9% to 4.0%. These drugs are generally used to help manage type 2 diabetes and obesity. This new partnership shows how FuturHealth wants its members to have all the right tools to achieve their weight loss goals through medications (if needed), nutrition and fitness.
Apple Fitness Plus is one of CNET's favorite workout apps thanks to its versatility and various exercise selections. Even if you aren't a FuturHealth member, the app itself is affordable at only $11 a month, giving you access thousands of workouts of different fitness modalities. Whether you have 5 minutes or 45 minutes, it has a workout you can stream on your iPhone, iPad and Apple TV.
Even if you're on one of these weight loss medications, movement is still important. And Apple is just one of the big brands that have identified a target audience in GLP-1 users. The fitness industry is rethinking strategies to better understand and support clients on weight loss medication, and even businesses like the travel and restaurant industries are finding ways to attract people who take this medication, whether through offering wellness retreats or changing up menu items.
It will be interesting to see how GLP-1s and similar weight loss drugs continue to influence the wellness and fitness industry as businesses pivot to cater to this growing demographic.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
9 minutes ago
- Gizmodo
Handsoaps Recalled Over Bacteria That Can Cause Sepsis
Four brands of soap and skin products are being recalled by their manufacturer after they were discovered to potentially be contaminated with bacteria that can cause infections, and even lead to sepsis in immunosuppressed people, according to announcements from the FDA and DermaRite Industries. The products, DermaKleen, KleenFoam, DermaSarra, and PeriGiene, have been recalled nationwide in the U.S. and Puerto Rico over the bacteria Burkholderia cepacia (spelled as cepecia in the FDA press release), though the health agency didn't indicate how the contamination of the soaps may have occurred. The announcements from the FDA and DermaRite Industries also didn't state where the soaps and skin products were sold, though listings online suggest the soaps are often purchased by companies and institutions for use in public facilities. It's not clear how popular the products may be at physical retail stores where the average consumer might buy them for use in the home, though they are available at online retailers like Amazon. Neither DermaRite nor the FDA immediately responded to questions Monday. The FDA's description of the recalled products: 'In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis,' the company said in a statement posted online. 'To date, DermaRite has not received any reports of adverse events related to this recall.' Consumers who believe they're experiencing issues after using these products are encouraged to contact their doctors. The lot numbers and expiration dates for the recalled products, according to DermaRite: Consumers who have questions about the recall are encouraged to call Mary Goldberg at DermaRite Industries at the number 973-569-9000 x104, Monday through Friday, from 9:00 am to 5:00 pm ET, according to the company's press release. The company can also be reached by email at: [email protected].
Fast Company
9 minutes ago
- Fast Company
Social media users and health experts raise fresh concerns around kratom-containing drinks like Feel Free
A 'feel good' herbal supplement is facing backlash online after a number of social media users shared their stories of addiction and terrifying health effects. Feel Free is sold at many gas stations and retailers across the United States. That is where influencer Misha Brown first heard of the product. On July 25, he posted a now-viral video, recounting how a teenage boy tried stealing his wallet outside a gas station after he refused to purchase a Feel Free tonic for the boy. After Brown informed the cashier about what had just transpired, she pointed to Feel Free and told him that people were coming in multiple times a day to purchase the product. 'It's so addictive and people lose their minds,' Brown recalled the attendant telling him. His video now has over 23 millions views and has sparked a wave of media attention. Social media users and experts alike are warning people about the addictive effects of products containing kratom, NBC News reported. Launched in 2020, the drink is advertised online as for 'whenever you want a mood lift, a caffeine-free energy boost, or a little extra focus.' Notably, the ingredients in Feel Free's Classic tonic include kratom, a plant native to Southeast Asia that's known for its stimulant and opioid-like effects. Concerns around the ingredient and its effects are not new. Scott Gottlieb, then commissioner of the Food and Drug Administration (FDA), said in 2018 that evidence pointed to the presence of opioid compounds in kratom, that it acts in the brain the same way as opioids do, and that it comes with 'potential for abuse.' It is currently banned in five states, according to a report from the Congressional Research Service. On Reddit, a group dedicated to quitting Feel Free now has over 5,000 followers. Users have shared experiences that include skin infections, seizures, and stints in rehab. 'These drinks are insane and not only leave you financially ruined but also physically and mentally,' one user wrote in a recent post. Botanic Tonics, the company behind Feel Free, agreed to pay $8.75 million to settle a 2023 class action lawsuit that claimed it failed to warn consumers about the dangers of kratom. Without admitting wrongdoing, the company has since updated its labels to warn that the drink may in fact be habit-forming. People with a history of substance abuse are advised to avoid using it. Fast Company has contacted Botanic Tonics for comment. In July, the FDA announced that it is recommending scheduling action to control products containing 7-OH, a byproduct of the kratom plant. This recommendation does not apply to natural kratom leaf products. Following the announcement, Feel Free wrote that its Feel Free Classic tonic contains only natural leaf kratom, meaning the FDA's proposed action would not affect the drink. '7-OH products bear absolutely no resemblance to the natural leaf kratom products that are used by more than 23 million Americans,' the company states.
Medscape
9 minutes ago
- Medscape
FDA Okays Ketamine-Based Med for Post-Surgical Pain
The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical pain. 'This historic FDA approval…is a testament to years of dedicated development,' Fabio Chianelli, chairman and CEO of PharmaTher, said in a release. 'We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders,' he added. The company noted that it hopes to expand ketamine development into conditions such as Parkinson's disease, amyotrophic lateral sclerosis, depression, and complex regional pain syndrome. Its product has already received an orphan drug designation for the treatment of Rett syndrome. It added that, among psychedelic and 'psychedelic-adjacent' drugs, ketamine is the only one to be included on a list of Essential Medicines by the World Health Organization. The company initially announced that the FDA had set an approval goal date of April 2024 for KETARx. However, after 'minor deficiencies identified by Quality' were identified, the FDA assigned a new target date of October 2024. As reported by Medscape Medical News at the time, the FDA issued a complete response letter requesting additional information on the application. The final date of August 2025 was set after the company submitted the requested additional information.
